Dublin, March 27, 2025 (GLOBE NEWSWIRE) -- The "Fragile X Syndrome - Global Clinical Trials Review, 2025" clinical trials has been added to ResearchAndMarkets.com's offering. The clinical trial ...

Mavoglurant, initially developed for fragile X syndrome, shows promise in reducing cocaine use disorder. A Phase II clinical trial with 68 participants revealed significant reductions in cocaine ...

"The acceptance of our Fragile X syndrome OLE data as a podium presentation at AAN underlines the significant unmet need in FXS, and the potential for ZYN002 to become the first-and-only approved ...